

Partnering in Oncology



Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. Our ambition in oncology is to elevate current therapeutic standards and deliver first-in-class therapies with improved efficacy and tolerability. Together with our partners we are exploring a dual research approach, focusing on both cancer-cell-directed therapies and immune-oncology agents, to tackle one of the biggest challenges in animal health.

We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.

Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Cancer cell-directed pathways: Cell death and DNA damage control; Transcriptional regulation; Growth signalling; Tumor delivery technologies
- Immune cell-directed pathways: T-cell modulation; Myeloid cell-modulation; Tumor stromal factors; Tumor antigens.

Research Focus

- Focus on canine and feline oncology and cancer immunology
- Dual research approach in cancer cell-directed therapies and immune cell-directed therapies
- Searching for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities.

SCAN ME



Collaboration Driving Innovation

- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

Investing in Animal Health Innovation



450+ million EUR

R&D for new medicines



Global

R&D presence in Europe, N. America, Asia



~1,200

staff in R&D facilities worldwide



>250

innovation collaborations

Leveraging synergies with Human Pharma



Exchanging scientific knowledge and expertise



Access to data, models and back-up compounds

Meet the Team



Hervé Poulet

hervé.poulet@boehringer-ingelheim.com

